Cyanamid (Drops) Instructions for Use
Marketing Authorization Holder
Ivanovo Pharmaceutical Factory PJSC (Russia)
ATC Code
V03AA (Drugs for the treatment of chronic alcoholism)
Active Substance
Cyanamid (Grouping name)
Dosage Form
| Cyanamid | Oral drops 60 mg/1 ml: bottle or dropper bottle 5 ml, 10 ml, 15 ml, 20 ml, 25 ml or 50 ml |
Dosage Form, Packaging, and Composition
Oral drops in the form of a transparent, colorless solution with a faint odor of acetic acid.
| 1 ml | |
| Cyanamid | 60 mg |
Excipients: sorbic acid, acetic acid, sodium acetate trihydrate, purified water.
5 ml – bottles with dropper caps (1) – cardboard boxes.
10 ml – bottles with dropper caps (1) – cardboard boxes.
15 ml – bottles with dropper caps (1) – cardboard boxes.
20 ml – bottles with dropper caps (1) – cardboard boxes.
25 ml – bottles with dropper caps (1) – cardboard boxes.
50 ml – bottles with dropper caps (1) – cardboard boxes.
5 ml – dropper bottles (1) – cardboard boxes.
10 ml – dropper bottles (1) – cardboard boxes.
15 ml – dropper bottles (1) – cardboard boxes.
20 ml – dropper bottles (1) – cardboard boxes.
25 ml – dropper bottles (1) – cardboard boxes.
50 ml – dropper bottles (1) – cardboard boxes.
5 ml – bottles with pipette caps or dropper caps (1) – cardboard boxes.
10 ml – bottles with pipette caps or dropper caps (1) – cardboard boxes.
15 ml – bottles with pipette caps or dropper caps (1) – cardboard boxes.
20 ml – bottles with pipette caps or dropper caps (1) – cardboard boxes.
25 ml – bottles with pipette caps or dropper caps (1) – cardboard boxes.
50 ml – bottles with pipette caps or dropper caps (1) – cardboard boxes.
Clinical-Pharmacological Group
Drug for the treatment of alcohol dependence
Pharmacotherapeutic Group
Other agents for the treatment of nervous system diseases; agents used for addictive disorders; agents used for alcohol dependence
Pharmacological Action
A drug for the treatment of chronic alcoholism. The mechanism of action is due to the blockade of aldehyde dehydrogenase, which is involved in the metabolism of ethanol.
Blockade of this enzyme leads to an increase in the concentration of an ethanol metabolite – acetaldehyde, which causes negative sensations (including flushing of the face, nausea, tachycardia, shortness of breath) that make alcohol consumption extremely unpleasant after taking cyanamide.
This leads to a conditioned reflex aversion to the taste and smell of alcoholic beverages.
The sensitizing effect of cyanamide on alcohol appears earlier (approximately after 45-60 minutes) and lasts shorter (about 12 hours) than the effect of disulfiram.
Unlike disulfiram, Cyanamid does not have a hypotensive effect and has lower intrinsic toxicity.
In addition, Cyanamid has greater specificity of action: unlike disulfiram, it blocks only aldehyde dehydrogenase and does not affect other enzymes, in particular dopamine-beta-hydroxylase.
Indications
Treatment of patients with chronic alcoholism; prevention of relapse of chronic alcoholism after treatment.
ICD codes
| ICD-10 code | Indication |
| F10.2 | Chronic alcoholism |
| ICD-11 code | Indication |
| 6C40.2Z | Alcohol dependence, unspecified |
| 6C40.Z | Disorders due to alcohol use, unspecified |
| 8D44.Y | Other specified alcohol-related neurological disorders |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer Cyanamid only after a comprehensive patient examination and receipt of informed consent.
Warn the patient thoroughly about all potential complications and consequences of therapy.
Initiate treatment no sooner than 12 hours after the patient’s last alcohol consumption.
Prescribe orally twice daily according to an individualized regimen.
Adjust the dosage based on patient tolerance and therapeutic response.
Ensure the patient understands the severe reaction that occurs with concurrent alcohol intake.
Monitor the patient regularly for adherence and any adverse effects.
Exercise increased caution in patients with hyperthyroidism, diabetes mellitus, or epilepsy.
With long-term use, monitor thyroid function at least once every six months.
Discontinue therapy and reassess if severe adverse reactions or intolerance occurs.
Adverse Reactions
Sometimes feeling of fatigue, drowsiness, skin rash, tinnitus, transient leukocytosis.
Cyanamid is generally well tolerated if the patient does not consume alcohol.
Contraindications
Severe diseases of the cardiovascular system; diseases of the respiratory system; kidney diseases accompanied by impaired function; severe liver diseases; pregnancy, breastfeeding; hypersensitivity to cyanamide.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and breastfeeding.
Use in Hepatic Impairment
Contraindicated in severe liver diseases.
Use in Renal Impairment
Contraindicated in kidney diseases accompanied by impaired function.
Special Precautions
Cyanamid should be used only under medical supervision and with the patient’s consent to the therapy.
One should be aware of the possibility of a reaction to ethanol contained in some medicines and food products.
Treatment with cyanamide should be started only after 12 hours have passed since the last alcohol consumption.
When alcohol is taken simultaneously, pronounced skin hyperemia, sensation of pulsation in the head and neck, nausea, tachycardia, difficulty breathing, weakness, blurred vision, increased sweating, chest pain may occur.
In the most severe cases: vomiting, decreased blood pressure, respiratory depression, collapse-like state.
The manifestations and their severity depend on the dose of cyanamide and the amount of alcohol consumed.
In severe cases, symptomatic therapy aimed at maintaining the functions of the respiratory and cardiovascular systems, intravenous administration of antihistamines is carried out.
Cyanamid should be used with caution in cases where the patient’s reaction to simultaneous alcohol consumption may pose a risk to the patient’s health: in hyperthyroidism, diabetes mellitus, epilepsy, cardiovascular diseases, kidney diseases.
With long-term use of cyanamide, it is recommended to monitor thyroid function at least once every 6 months.
Drug Interactions
Cyanamid should not be used simultaneously with metronidazole, isoniazid, phenytoin and other inhibitors of aldehyde dehydrogenase – this may enhance the reaction to alcohol consumption.
There should be a break of at least 10 days between the use of disulfiram and the prescription of cyanamide.
Cyanamid is incompatible with drugs of the aldehyde group (paraldehyde and chloral products).
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer